---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-027969"
form_type: "8-K"
ticker: "AKTX"
cik: "0001541157"
company_name: "Akari Therapeutics Plc"
filed_at: "2025-12-16T23:59:59+00:00"
generated_at: "2026-05-16T13:02:56.616997+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Akari shareholders approve share sub-division, warrant exercise, and new articles

## Summary
- Approved exercisability of warrants issued in October 2025 offering under Nasdaq Listing Rule 5635(d).
- Approved sub-division and re-designation of ordinary shares into 1 ordinary share (0.000000005 GBP) and 19,999 deferred shares.
- Authorised directors to allot shares up to nominal amount of USD 3,000, expiring June 30, 2030.
- Approved a share buyback contract for all deferred shares and adoption of new articles of association.
- Special resolution passed to allot equity securities for cash without pre-emption rights, effective for five years.

## SEC filing metadata
- accession: 0001493152-25-027969
- form_type: 8-K
- ticker: AKTX
- cik: 0001541157
- company_name: Akari Therapeutics Plc
- filed_at: 2025-12-16T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1541157/000149315225027969/0001493152-25-027969-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1541157/000149315225027969/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-027969
- JSON: https://secwatch.observer/filing/0001493152-25-027969.json
- Plain text: https://secwatch.observer/filing/0001493152-25-027969.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.